The US Food and Drug Administration will continue remote regulatory assessments of drug manufacturing plants, clinical investigator sites and other regulated facilities after the COVID-19 pandemic no longer prevents travel for site inspections, the agency says in a draft guidance.
In a notice scheduled for publication in the 25 July Federal Register, the agency also offers some insight into why it will continue RRAs. The experience it developed with various...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?